SCNN1B
SCNN1B is a gene that encodes the beta subunit of the epithelial sodium channel (ENaC). ENaC is a part of the aldosterone-sensitive sodium reabsorption pathway in the kidney, lung, and sweat glands. Mutations in this gene have been associated with a variety of conditions, including Liddle syndrome, pseudohypoaldosteronism type 1 (PHA1), and cystic fibrosis.
Function[edit]
The SCNN1B gene is responsible for the production of the beta subunit of the epithelial sodium channel (ENaC). This channel is found in the plasma membrane of many epithelial cells, where it allows for the passage of sodium ions into the cell. The activity of ENaC is regulated by the hormone aldosterone, which is produced by the adrenal gland in response to low blood volume or low sodium concentration.
Clinical significance[edit]
Mutations in the SCNN1B gene can lead to a variety of conditions. For example, Liddle syndrome is a rare genetic disorder characterized by early-onset hypertension, low levels of aldosterone, and suppressed plasma renin activity. This condition is caused by gain-of-function mutations in the SCNN1B gene that result in increased activity of ENaC.
Pseudohypoaldosteronism type 1 (PHA1) is another condition associated with mutations in the SCNN1B gene. PHA1 is characterized by salt wasting, hyperkalemia, and metabolic acidosis. This condition is caused by loss-of-function mutations in the SCNN1B gene that result in decreased activity of ENaC.
In addition, mutations in the SCNN1B gene have been associated with cystic fibrosis, a condition characterized by the buildup of thick, sticky mucus that can damage many of the body's organs.
See also[edit]
References[edit]
SCNN1B gallery[edit]
-
SCNN1B gene transcript
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian